EBITDA Margin ratio Analysis of Halozyme Therapeutics Inc - Deep Dive
Birds's Eye
Fundamentals
Fundamentals
Technicals
MovingAverage
Candlestick
PivotPointLatest FY EBITDA Margin
Period Ending - Dec-23
Excellent EBITDA Margin
50.94
Period Ending - Dec-22
Excellent EBITDA Margin
47.80
Growth
6.58 %
Trailing Twelve Months EBITDA Margin
Period Ending - Dec-23
Excellent EBITDA Margin
46.35
Most recent Quarter EBITDA Margin
Period Ending - Mar-24
Excellent EBITDA Margin
48.78
EBITDA Margin Analysis of Halozyme Therapeutics Inc
| Ebitda Margin Ratio of Halozyme Therapeutics Inc with value of 46.35 means that its operating expenses are lower in relation to total revenue in trailing twelve months. |
| Ebitda Margin Ratio of Halozyme Therapeutics Inc with value of 48.78 means that its operating expenses are lower in relation to total revenue latest Quarter ending on Mar-24. |
| EBITDA Margin Ratio of HALO has grown by 6.58 % Compared to previous Financial Year. |
| EBITDA Margin Ratio with value of 58.43 was highest in Year Dec-21 in last Five Years. |
| EBITDA Margin Ratio with value of -28.86 was lowest in Year Dec-19 in last Five Years. |
| Latest EBITDA Margin Ratio with value of 50.94 is Greater than Average EBITDA Margin of 37.10 in last five years. |
Other EBITDA Margin Related Info of HALO that may interest you.
Halozyme Therapeutics Inc Overview
| Code | Price | Previous Price | Price Change | Sector |
|---|---|---|---|---|
| HALO | 44.29 | 43.35 | 2.17 % | Biotechnology |
Defination of EBITDA Margin
EBITDA Margin is the profitability ratio that measures a company's earnings before interest, taxes, depreciation, and amortization as a percentage of revenue. EBITDA is the abbreviation for Earnings before Interest, Taxes, Depreciation, and Amortization. more ..
EBITDA Margin Related Ratios
| NetProfitMargin | ReturnOnEquity |
Tsr Profitability Index
| Mild Profitability | |
FY - Historical EBITDA Margin of Halozyme Therapeutics Inc
| Period | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 |
|---|---|---|---|---|---|---|---|
| EBITDA Margin | 50.94 | 47.80 | 58.43 | 57.16 | -28.86 | -39.09 | 27.09 |
| Change | 6.58 % | -18.21 % | 2.22 % | 298.09 % | 26.18 % | -244.33 % | 149.99 % |
FY Chart of EBITDA Margin of Halozyme Therapeutics Inc
Note : All Data Generated at the End of Trading Hours (EOD Data)